News

About 1 in 7 treated swelling attacks in people with hereditary angioedema (HAE) required an additional dose of on-demand medication, with attack severity and treatment characteristics emerging as the main factors associated with retreatment, according to a real-world study from the Czech Republic that examined more than 8,000…

People with hereditary angioedema (HAE) have a higher risk of developing post-traumatic stress disorder (PTSD), a mental health condition triggered by exposure to psychological stress, according to a new study. Researchers also found that a PTSD diagnosis correlated with high rates of depression and reduced mental health-related quality of…

An international registry collecting real-world data from people with recurrent angioedema — marked by repeated swelling episodes — has enrolled more than 500 patients across 18 countries in its first two years, according to a new study. The database’s rapid expansion shows it’s already becoming “a robust global real-world…

The Angioedema Quality of Life Questionnaire (AE-QoL) is a reliable and effective tool for measuring the impact of hereditary angioedema (HAE) on patients’ day-to-day lives — and can also detect meaningful improvements when the genetic disease becomes better controlled. That’s according to an analysis of data from OASIS HAE…

The investigational therapy barzolvolimab rapidly reduced angioedema in people with chronic spontaneous urticaria (CSU) in a Phase 2 trial, and many remained free of swelling months after treatment ended. At the trial’s final assessment, conducted at week 76 (about 17.5 months after the study began), as many as 64%…

Children and young adults with angioedema rarely require airway management to ensure an open passage for airflow, but when they do, it usually indicates more severe disease associated with longer hospital stays, higher costs, and a greater risk of death. Those are the findings of a new study by…

Among people with hereditary angioedema (HAE), the one-time gene-editing therapy lonvoguran ziclumeran — simply called lonvo-z — significantly reduces the frequency of swelling attacks, minimizes the need for on-demand treatment, and improves quality of life. These are the newest findings from a global Phase 3 clinical trial, dubbed…

Local cytokine release syndrome (L-CRS) is a potentially underrecognized complication of CAR T-cell therapy for blood cancer that can appear as cervical angioedema, or swelling in the deeper layers of tissue in the neck or throat, a study suggests. The swelling may occur after a bodywide inflammatory response has…

A six-month dosing regimen of Argo Biopharma‘s long-acting investigational therapy BW-20805 reduced monthly attacks in people with hereditary angioedema (HAE) by up to 99%. That’s according to new data from an ongoing open-label Phase 2 clinical trial (NCT06846398) testing the therapy in up to 25 adults, ages…

While there is a connection between angioedema and the use of angiotensin-converting enzyme inhibitors (ACEIs), a class of medications commonly used to manage cardiovascular problems, certain people with the condition can safely use ACEIs. That’s according to a Dutch study that examined primary care for people with angioedema…